Introduction
The 18 kDa translocator protein (TSPO), previously known as the peripheral benzodiazepine receptor (PBR), is strongly expressed in microglia and macrophages (Papadopoulos et al, 2006) . For this reason, the TSPO-targeting positron emission tomography (PET) radioligand, [
11 C]PK11195, has been applied to studying disease processes that involve microglial activation or the recruitment of macrophages, such as multiple sclerosis (MS), ischaemic stroke, herpes encephalitis, Parkinson's disease, or Alzheimer's disease (Banati et al, 2000; Cagnin et al, 2001; Edison et al, 2008; Gerhard et al, 2006; Ramsay et al, 1992) . The TSPO is an attractive target for this application as it is expressed only at low levels in the healthy human brain (Doble et al, 1987) . The TSPO exists both as a monomer and as part of a multimeric complex involving several TSPO monomers with associated proteins, including the voltage-dependent anion channel (Boujrad et al, 1994 (Boujrad et al, , 1996 Rao and Butterworth, 1997) . Although subunit interactions are not necessary for drug ligands to bind the TSPO monomer (Joseph-Liauzun et al, 1997; Lacapere et al, 2001) , binding of some drugs to the TSPO is influenced by these interactions (Golani et al, 2001) .
It is well recognised that in vivo PET applications of [ 11 C]PK11195 are limited by the low affinity and low extraction in brain, resulting in poor signal-to-noise ratio (Banati et al, 2000) . There has therefore been considerable interest in developing improved TSPO tracers, and various candidate molecules have been generated, including PBR06 (Imaizumi et al, 2007) , FEPPA (Wilson et al, 2008) , DAA1106 (Okubo et al, 2004) , and PBR111 (Fookes et al, 2008) . This paper explores [ 11 C]PBR28, a new TSPO-targeting PET radioligand, which has a favourable specific-to-nonspecific binding ratio . [ 11 C]PBR28 is displaced by unlabelled PK11195 and unlabelled PBR28 displaces [ 3 H]PK11195 ), but it is not known whether PK11195 and PBR28 bind the same site on the TSPO.
A recent clinical PET study using [ 11 C]PBR28 has reported that 14% of healthy volunteers did not have a specific binding signal in either the brain or the peripheral organs . The reason for this is not fully understood. Various hypotheses can be entertained, including conformational changes in the TSPO molecule, displacement by endogenous factors, reduction in expression, or pharmacokinetic factors preventing the radiotracer from reaching the TSPO target.
In this paper, we use frozen section autoradiography to confirm the observation of apparent PBR28 nonbinding, and then directly compare the quantitative binding of 
Materials and methods

Human Tissue
Tissue from donors 1 to 6 inclusive was obtained from the UK National Multiple Sclerosis (MS) Brain Bank for an initial pilot study. Samples from 16 further donors were later obtained from the same source to increase the sample size. Of the 22 donors, 20 had been diagnosed with MS, and 2 were control donors without MS, neuropathological reports for which showed age-related changes only. Initial autoradiography results identified five apparent PBR28 nonbinding subjects. Tissue blocks from these subjects were obtained for quantitative binding studies. We also randomly selected tissue blocks from 10 individuals with apparently normal PBR28 binding to serve as comparisons in these studies.
Tissue Used in Autoradiographical Studies
Tissue blocks were sectioned (10 mm thickness) using a cryostat microtome (Leica, Wetzlar, Germany; CM1900) and thaw-mounted onto superfrost glass microscope slides. Slides were stored at À801C until use. For donors 1 to 6 inclusive, tissue was sectioned specifically for the study and used within 14 days of sectioning. For the remaining donors, the tissue had been sectioned up to 300 days before use.
Tissue Used in Homogenate and Competition Binding Assays
Tissue blocks contained histopathologically 'normal appearing' tissue, without immunohistochemical evidence of demyelination or significant inflammatory infiltrate. The tissue was stored at À80 o C until use. Demographic, tissue handling, and clinical information regarding the donor is shown in Table 1 . Autoradiography binding studies were performed on the sectioned human tissue using the optimised experimental conditions. Briefly, sections from each donor were thawed to room temperature (RT) and washed for 15 minutes in assay buffer (50 mmol/L Tris Base, 140 mmol/L NaCl, 1.5 mmol/L MgCl 2 , 5 mmol/L KCl, 1.5 mmol/L CaCl 2 , pH 7.4, RT). Sections were incubated in assay buffer containing either [ in X-ray cassettes at RT (4 weeks). After development of the radiograms, the films were quantified using microcomputer imaging device analysis software (Microcomputer Imaging Device Core 7.0; Interfocus Imaging Ltd, Linton, UK). Regions of interest (ROIs) were generated for each area of (unless otherwise stated) nondiseased grey matter on each tissue section. Nondiseased grey matter was defined as an area of grey matter with no microscopic evidence of demyelination or inflammation, as defined by the immunohistochemical stains outlined below. Values were converted to fmol [ 3 H]ligand/mg wet tissue equivalent using the calibrated [ H]PK11195 were used, ranging from 100 pmol/L to 100 nmol/L. The nonspecific binding component was defined by addition of unlabelled PK11195 (10 mmol/L) to adjacent sections. Regions of interests were placed on nondiseased grey matter for autoradiograph quantification unless otherwise stated.
Immunohistochemistry
Sections adjacent to those used for frozen section autoradiography were stained with antibodies to identify microglia/macrophages (CD68 (DAKO, Ely, UK), major histocompatibility complex class II (Abcam, Cambs, UK)), and with antimyelin oligodendrocyte glycoprotein (antibody provided: courtesy of R Reynolds, Imperial College London) to define demyelination. This was performed for donors 1 to 6 inclusive, but was not possible for the remaining donors because of insufficient tissue.
Membrane Preparation
Tissue blocks, obtained from 15 of 22 donors, were homogenised in 10 times weight for volume buffer (0.32 mmol/L sucrose, 5 mmol/L Tris-Base, 1 mmol/L MgCl 2, pH 7.4, 41C). Homogenates were centrifuged (32,000 Â g, 20 minutes, 41C) followed by removal of the supernatant. Pellets were resuspended in at least 10 times w/v (weight for volume) buffer (50 mmol/L Tris-Base, 1 mmol/L MgCl 2 , pH 7.4, 41C) followed by two washes by centrifugation (32,000 Â g, 20 minutes, 41C). Membranes were suspended in buffer (50 mmol/L Tris-Base, 1 mmol/L MgCl 2 , pH 7.4, 41C) at a protein concentration of approximately 4 mg protein/mL and aliquots were stored at À801C until use.
Homogenate and Competition Binding Assays
Aliquots (approximately 250 mg protein/mL) of membrane suspension were prepared using assay buffer (50 mmol/L Tris-Base, 140 mmol/L NaCl, 1.5 mmol/L MgCl 2 , 5 mmol/L KCl, 1.5 mmol/L CaCl 2 , pH 7.4, 371C) and incubated with [ ]PBR28 were used, ranging from 100 pmol/L to 1000 nmol/L. The specific binding component associated for both radioligands was defined by addition of unlabelled PK11195 (10 mmol/L). After incubation, assays were terminated by filtration through Whatman GF/B filters (Whatman, Maidstone, UK), followed by 3 Â 1 mL washes with icecold wash buffer (50 mmol/L Tris-Base, 1.4 mmol/L MgCl 2 , pH 7.4, 41C). Whatman GF/B filters were preincubated with 0.05% polyethyleneimine (60 minutes) before filtration. Scintillation fluid (3 mL/vial, Perkin Elmer Ultima Gold MV) was added and vials counted on a Perkin Elmer Tricarb 2900 liquid scintillation counter. Each point was performed in triplicate. B max (fmol per mg protein) and K d (nmol/L) values were determined using GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, USA).
Competition assays were performed under the same conditions as the homogenate binding assays above. Each assay well contained [ 3 H]PK11195 (4 nmol/L) with unlabelled PK11195 (10 concentrations ranging from 0.1 nmol/L to 3 mmol/L) or unlabelled PBR28 (12 concentrations ranging from 0.1 nmol/L to 30 mmol/L). The specific binding component was determined using unlabelled PK11195 (10 mmol/L). For each donor, each point was performed in triplicate, except for the total and nonspecific wells that were performed in sextuplicate.
Protein Concentration Determination
Protein concentrations (mg protein/mL) were determined using the bicinchoninic acid assay (BCA Kit, SigmaAldrich, Gillingham, UK) and absorption read at 562 nm.
Data Analysis
All saturation and competition data were analysed using the iterative nonlinear regression curve-fitting software supplied with GraphPad Prism 5.0. Single-site and two-site models were compared using the least-squares algorithm. The null hypothesis, that the data fitted a single-site model, was rejected if the P-value was less than 0.05. The mean K d value for [ 3 H]PK11195 was used to generate the K i for unlabelled PBR28 and PK11195. Autoradiography tissue ROIs were quantified on the total sections and ROIs were aligned with the adjacent nonspecific binding section, to determine the specific binding component. All data were analysed independently and are expressed as the mean±s.d. Student's t-test (GraphPad Prism) was used to determine the statistical significance.
Results
Localisation of Binding-Frozen Section Autoradiography
All six donors in the pilot study produced a specific binding signal with [
3 H]PK11195 in both grey and white matter. The specific binding signal associated with [
3 H]PK11195 in normal grey matter was higher than in normal white matter, allowing the two to be clearly distinguished by visual inspection (Figure 1 ). In donors with MS, there were also well-defined areas of high specific binding within the white matter, consistent with the expected shape, size, and distribution of the inflammatory lesions characteristic of MS. 1 and Supplementary Table) . These two donors did not differ from others with regard to demographics or disease expression (Table 1) .
Tissue from all six donors was examined using immunohistochemistry. In two of the six donors who were healthy controls without MS, immunohistochemistry revealed no pathology. In three of the Figure 1 Representative images for total and nonspecific binding in a high affinity binder (Donor 1) and a low-affinity binder (Donor 5) Figure 2B , Table 2 ). For the four donors (all HABs) for which a best fit was found with a twosite model, the mean K d for the high-and low-affinity sites were 1.3 ± 0.2 and 135 ± 161 nmol/L, respectively. Hereafter, we refer to this group (a subset of HABs) as mixed-affinity binders (MABs).
The B max for LABs (994 ± 353 fmol per mg protein) was lower than that obtained for HABs (1929 ± 657 fmol per mg protein, P = 0.02) ( Figure 2D , Table 2 (Table 2) .
Estimation of K i -Competition Binding Studies
To accurately assess binding at the low-affinity site for [
3 H]PBR28 in tissue from the four MABs, high concentrations of radioligand would be required and self-block would be a concern, because only a small fraction of the ligand is successfully labelled. Competition binding assays were therefore performed. Results from these assays consistently fitted to a single-site model for PK11195, with K i values that were not significantly different between HABs (26.4±10.0 nmol/L) and LABs (22.3±4.9 nmol/L) (P = 0.41) (Table 3, Figure 3A ). Competition assays using unlabelled PBR28 confirmed a single-site best fit in tissue from the 11 donors who had previously shown a single-site fit in [ 3 H]PBR28 saturation studies. The difference in affinity for HABs (K i 3.40 ± 0.5 nmol/L) and LABs (K i 188±15.6 nmol/L) was consistent with saturation studies (Table 3) .
Competition data also confirmed the two-site fit for the four MABs who had previously shown a two-site fit in the saturation study with [ 3 H]PBR28 ( Figure 3B ). The mean K i for the MAB low-affinity binding site from the competition assays was 313 nmol/L, and the confidence intervals for this estimate (191 to 435 nmol/L) overlapped with the confidence intervals for the estimate of the LAB site (169 to 207 nmol/L). This raises the possibilities that (1) the LAB site and the lower-affinity MAB site may be the same site, and, if so, (2) MABs may express both a HAB and an LAB site. To investigate these hypotheses, we fitted the data from the competition assays to the equations below, which assume that MABs have an equal number of high-and lowaffinity binding sites ( Figure 3B ). When fitted in this manner, the affinities for the high-and low-affinity sites were estimated to be 5.4 and 172 nmol/L, respectively. We explored the data further and removed the constraint fixing the two sites to a 50:50 distribution. This analysis suggested that the two sites were distributed at 43:57 (high/low) with affinities of 4.6 and 145 nmol/L, respectively.
HABs:
where SP is the specific binding of [ 3 H]PK11195; NS, nonspecific binding; and f H , the fraction of high-affinity binding sites.
Discussion
We have compared the binding characteristics of the novel TSPO ligand, PBR28, with the those of the previously characterised TSPO radioligand, PK11195 (Doble et al, 1987) , in tissue from human brain. Autoradiography revealed that tissue from 5 of the 22 donors (23%) did not show a measurable binding signal after incubation with [ 3 H]PBR28 at a concentration close to the reported K i of 2.5 nmol/L 26.4±10.0 (n = 10) 3.4±0.5 (n = 6) 4.0±2.4 (n = 4) 313±76.8 (n = 4) 0.52±0.07 (n = 4) 22.3±4.9 (n = 5) 188±15.6 (n = 5)
T-test (HABs versus LABs)
HABs, high-affinity binders; LABs, low-affinity binders. a Data did not fit a single-site model and was therefore excluded from calculation of mean K i .
[ 3 H]PBR28 binding in the human brain DR Owen et al 3 H]PBR28 also showed a marked decrease in affinity, which was similar in magnitude to that observed in the homogenate saturation studies. The affinity of [ 3 H]PK11195 for the TSPO was the same for all donors and this radioligand was not able to distinguish the groups in either the homogenate or the autoradiographical studies. We thus can reject the hypothesis that the absence of PBR28-specific binding is because of an absence of TSPO, and propose classifying subjects as LABs or HABs, consistent with results from a recent report showing a reduction in PBR28 affinity in lymphocytes from volunteers who showed no specific [
11 C]PBR28 signal with PET (Kreisl et al, 2010) .
The density of TSPO binding sites for [ 3 H]PK11195 was similar for all subjects. In contrast, the density of TSPO binding sites exhibited by [ 3 H]PBR28 was lower for the LABs relative to the HABs. This result must be interpreted with caution, because our sample size is limited. However, we hypothesise that a true difference in B max between HABs and LABs may exist, possibly as a consequence of differences in TSPO or interactions with associated proteins arising from the structural or functional changes responsible for the difference in affinities.
Although one report has speculated that PK11195 may have a low-affinity binding site (Broaddus and Bennett, 1990) , the majority of literature published earlier (Doble et al, 1987; Miyazawa et al, 1998; Rao and Butterworth, 1997; Venneti et al, 2008) found evidence for only a single site. Our study supports this conclusion. However, our saturation studies revealed a subgroup (4 of the 10 HABs) with two distinguishable PBR28 binding sites that we label as MABs. Competition binding assays confirmed this. We estimated the K i for the MAB low-affinity site (313 nmol/L) as being similar to the K i of the LAB site (188 nmol/L), and the K i for the MAB high-affinity site (4.0 nmol/L) as being similar to the K i of the HAB site (3.4 nmol/L). Given the two MAB sites are represented in approximately equal proportion, we speculate that the MABs are heterozygotes for a codominantly expressed binding site, whereas HABs and LABs are homozygotes for alternative forms. This is consistent with our modelling data, which estimated the two binding sites to have affinities of 4.6 and 145 nmol/L, respectively, with a distribution approximating 50:50. For an allele frequency to be broadly consistent with the proportions of HABs (46%), MABs (31%), and LABs (23%) in the general population, predicted by our enriched sample, it would need to be distributed in the population in a ratio of approximately 2:3 (HAB allele) to 1:3 (LAB allele). However, the known single-nucleotide polymorphisms of the gene encoding the TSPO, His162Arg and Ala147Thr, have distributions of 79:21 and 98:2, respectively (Kurumaji et al, 2000) . Nevertheless, this does not exclude the possibility that a single-nucleotide polymorphism underlies the different binding states, because our sample is comprised mainly of patients with MS. If MS is associated with either of the two known single-nucleotide polymorphisms, then the single-nucleotide polymorphism distribution in our sample may differ from that in the general population. Similar work is required with control brains to determine whether the MAB state is detected, and if so the relative frequencies of HABs, MABs, and LABs.
The presence of differing affinity profiles is problematic for the interpretation of PET data, as differences in the binding parameters of [
11 C]PBR28 cannot be assumed to reflect differences in the density of TSPO. Regardless of which measure of binding potential is calculated, for a given receptor density the binding potential will be in the ratio of 55:28:1 for HABs, MABs, and LABs, respectively (assuming that MABs express equal numbers of HAB and LAB sites, which have affinities of 3.4 and 188 nmol/L, respectively). As LABs are easily identifiable and therefore easily eliminated from a cohort, it will be difficult to differentiate MABs with an elevated TSPO density from HABs in whom TSPO density is normal. Assuming binding status remains constant over time, intra-patient comparisons required to measure the effect of treatment or disease progression may still be feasible. Assuming that binding status is consistent across different tissues (centrally and peripherally), inter-patient comparisons would also still be feasible by classifying the subjects into groups (HABs, MABs, or LABs) on the basis of binding assays of peripheral blood cells. In theory, population corrections could then be applied to compare subjects in different binding groups. Although early evidence suggests that LAB and HAB status may remain constant over time and across tissue (Kreisl et al, 2009) (Rao and Butterworth, 1997) , rat, guinea pig, cat, and calf (Awad and Gavish, 1989) . Tissue handling influenced autoradiography binding of the two radioligands in different ways. The specific signal from [ 3 H]PK11195 was significantly lower in tissue sections that had been stored long term, compared with the tissue that had been stored as a tissue block and sectioned just before use. However, no significant differences were observed with [ 3 H]PBR28 between the two groups. In separate pilot experiments conducted before those reported here, we also observed that fixation with paraformaldehyde markedly reduces PBR28 binding but has no discernable effect on PK11195 binding (data not shown).
Our conclusion that there are distinct binding sites for the two radioligands has precedent. Ro5-4864 shows a two-site fit in the cerebral cortex of rat, mouse, guinea pig, rabbit, and calf Gavish, 1987, 1989; Eshleman and Murray, 1989) , as well as rat and calf kidney (Awad and Gavish, 1989) . A second site is expressed transiently in a murine Leydig cell line after stimulation with human chorionic gonadotropin (Boujrad et al, 1994) . However, in an earlier study using human brain tissue from six donors, a second site was not reported (Rao and Butterworth, 1997) .
It was previously suggested that PK11195 binds the TSPO itself, whereas Ro5-4864 (although it can bind the isolated TSPO) binds only one TSPO molecule within the multimeric functional complex (Rao and Butterworth, 1997) , which is formed by clusters of four to six TSPO molecules associated with proteins, including the voltage-dependant anion channel (Boujrad et al, 1994 (Boujrad et al, , 1996 Rao and Butterworth, 1997) . This model is consistent with the lower B max for Ro5-4864 and the observation that the voltage-dependant anion channel enhances Ro5-4864 binding but has no effect on PK11195 binding (Lacapere et al, 2001 ). We speculate that, similar to Ro5-4864, PBR28 binds only a fraction of TSPO molecules within the multimeric complex. PBR28 binding may displace PK11195 by causing a conformational change transmitted allosterically across the TSPO binding site. Further studies are required to test this hypothesis.
We appreciate that the B max and K d values we report using [ 3 H]PK11195 on the control and MS donor tissue are higher than those in previous reports published (Doble et al, 1987; Miyazawa et al, 1998; Rao and Butterworth, 1997; Venneti et al, 2008) . However, previous pharmacological assays were performed almost exclusively at 41C or RT, whereas our assays were performed at 371C (to generate data that are potentially more readily related to in vivo PET data). It is not unusual or unexpected for temperature to affect the binding properties of radioligands (Hall et al, 1988 (Hall et al, , 1990 ). Our autoradiography studies, which were performed at RT, produced K d values very similar to those reported previously (Doble et al, 1987; Miyazawa et al, 1998; Rao and Butterworth, 1997; Venneti et al, 2008) .
We thus have shown that PBR28 binding to human brain tissue can be described as high-affinity binding with a single site (HAB), low-affinity binding with a single site (LAB), or MAB with one high-and one lowaffinity site (MAB). In contrast, PK11195 appears to bind only in one way and shows similar affinity in all individuals. We therefore conclude that a difference in [ 11 C]PBR28 binding between subjects cannot be interpreted simply as a difference in TSPO density.
